Description
Alluvi Retatrutide 40mg offers researchers a premium alternative for studying triple agonist peptide mechanisms. Manufactured with strict quality controls, this product delivers consistent results for metabolic and longevity research.
Key Features:
• Triple agonist targeting GLP-1, GIP, and Glucagon receptors
• 40mg concentration per pen
• 4 doses of 10mg each
• Once-weekly dosing schedule
• Alluvi Healthcare pharmaceutical-grade formulation
• Complete kit with 12 disposable needles
Research Benefits:
Alluvi’s formulation has been optimized for stability and bioavailability. Researchers appreciate the consistent potency and reliability across multiple studies. The triple agonist approach allows investigation of synergistic receptor activation.
Storage & Handling:
Maintain at 2°C to 8°C (refrigerated). Each pen is individually sealed for maximum stability. Disposable needles ensure sterile administration for each dose.
Intended Use:
For research purposes only. Designed for subcutaneous injection studies in laboratory and clinical research settings.
⚠️ Research Disclaimer:
This product is intended for research purposes only. It is not intended for human consumption or medical use. Always consult with qualified professionals before use.
